Scrip
US FDA accepts Valeant and GSK's filing for anti-epileptic retigabine
04 January 2010
Katie McQue
04 January 2010
Katie McQue
The US FDA has accepted Valeant Pharmaceuticals and GlaxoSmithKline's NDA for their anti-epileptic candidate retigabine as an adjunctive therapy for adult epilepsy patients with partial-onset seizures.
The drug was filed in both the US and EU in October (
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Face-to-Face: Allon targets tau pathology with lead drug davunetide
- Xention looks to ion technology to jump start safer treatments
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
